



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	349784	BLACKMORES CRANBERRY FORTE 50,000
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Blackmores Ltd	
<b>Postal Address</b>	PO Box 1725, WARRIEWOOD, NSW, 2102 Australia	
<b>ARTG Start Date</b>	26/11/2020	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . BLACKMORES CRANBERRY FORTE 50,000

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	26/11/2020
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce occurrence of medically diagnosed cystitis  
Maintain/support urinary tract health

#### Indication Requirements

Label statement: If pain or irritation persists for more than 48 hours, consult your doctor. The presence of blood in the urine warrants immediate medical attention (or words to that effect).  
Product presentation must only refer to medically diagnosed cystitis.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

No Warnings included on Record

#### Additional Product information

#### Pack Size/Poison information

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

#### Components

##### 1 . Formulation 1

<b>Dosage Form</b>	Capsule, hard
<b>Route of Administration</b>	Oral

#### Visual Identification

#### Active Ingredients

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

<b>Vaccinium macrocarpon fruit Extract dry concentrate</b>	<b>60 mg</b>
Equivalent: Vaccinium macrocarpon (Fresh)	30 g
<b>Vaccinium macrocarpon fruit Extract dry concentrate</b>	<b>400 mg</b>
Equivalent: Vaccinium macrocarpon (Fresh)	20 g

**Other Ingredients (Excipients)**

calcium phosphate  
colloidal anhydrous silica  
disodium edetate  
gellan gum  
hypromellose  
magnesium hydroxide  
magnesium stearate  
microcrystalline cellulose  
potable water  
potassium acetate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary